Uncovering The Potential of FBXO10 as A Drug Target (G26267)

Target Name: FBXO10

NCBI ID: G26267

FBXO10

Uncovering The Potential of FBXO10 as A Drug Target

FBXO10, also known as F-box only protein 10, is a protein that is found in various tissues throughout the body. It is a member of the F-box only protein family, which are a group of proteins that contain a specific domain known as an F-box. These proteins are known for their ability to interact with various molecules, including DNA, RNA, and proteins.

One of the unique features of FBXO10 is its unique structure. It consists of 20 amino acid residues and has a calculated molecular weight of 21.1 kDa. The protein has a distinct N-terminus, a catalytic center, and a C-terminus. The N -terminus is known for its ability to interact with DNA, while the C-terminus is known for its ability to interact with various proteins.

FBXO10 has been shown to play a role in various cellular processes throughout the body. For example, studies have shown that it is involved in the regulation of gene expression, DNA replication, and chromatin structure. It has also been shown to interact with various proteins , including transcription factors, DNA-binding proteins, and histone modifiers.

One of the potential uses for FBXO10 as a drug target is its involvement in the regulation of cancer progression. Studies have shown that FBXO10 is involved in the regulation of the growth and survival of various cancer cell lines. For example, researchers have shown that inhibiting the activity of FBXO10 can cause cancer cells to undergo a regression in their growth and spread.

Another potential use for FBXO10 as a drug target is its involvement in the regulation of neurodegenerative diseases. Studies have shown that FBXO10 is involved in the regulation of the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. For example, researchers have shown that inhibiting the activity of FBXO10 can cause neurodegenerative diseases to progress at a slower rate.

FBXO10 has also been shown to be involved in the regulation of inflammation. Studies have shown that FBXO10 is involved in the regulation of various inflammatory responses in the body. For example, researchers have shown that inhibiting the activity of FBXO10 can reduce the production of pro -inflammatory cytokines.

In conclusion, FBXO10 is a unique and fascinating protein that has the potential to be a drug target. Its unique structure and various functions make it an attractive target for research and development of new treatments for various diseases. Further studies are needed to fully understand the role of FBXO10 in the regulation of various cellular processes and to determine its potential as a drug target.

Protein Name: F-box Protein 10

Functions: Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex. Mediates the ubiquitination and degradation of BCL2, an antiapoptotic protein, thereby playing a role in apoptosis by controlling the stability of BCL2. Targets also the receptor for advanced glycation end products RAGE for ubiquitination and subsequent lysosomal degradation (PubMed:28515150). Directly controls HGAL/GCSAM ubiquitination and degradation and thereby decreases BCR signaling (PubMed:31570756)

The "FBXO10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXO10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets